TW200306866A - A method to improve surface properties of pharmaceutical tablets - Google Patents
A method to improve surface properties of pharmaceutical tablets Download PDFInfo
- Publication number
- TW200306866A TW200306866A TW092108690A TW92108690A TW200306866A TW 200306866 A TW200306866 A TW 200306866A TW 092108690 A TW092108690 A TW 092108690A TW 92108690 A TW92108690 A TW 92108690A TW 200306866 A TW200306866 A TW 200306866A
- Authority
- TW
- Taiwan
- Prior art keywords
- lozenges
- tablets
- cellulose ether
- surface properties
- cellulose
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 26
- 229920003086 cellulose ether Polymers 0.000 claims abstract description 15
- 239000002904 solvent Substances 0.000 claims abstract description 15
- 239000011159 matrix material Substances 0.000 claims abstract description 8
- 239000007937 lozenge Substances 0.000 claims description 35
- 239000011230 binding agent Substances 0.000 claims description 6
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 3
- 238000010586 diagram Methods 0.000 claims 1
- 239000003826 tablet Substances 0.000 description 29
- 239000002245 particle Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000000428 dust Substances 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 239000011248 coating agent Substances 0.000 description 12
- 238000000576 coating method Methods 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- 239000003125 aqueous solvent Substances 0.000 description 5
- 238000005507 spraying Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- QOIGKGMMAGJZNZ-UHFFFAOYSA-N gepirone Chemical compound O=C1CC(C)(C)CC(=O)N1CCCCN1CCN(C=2N=CC=CN=2)CC1 QOIGKGMMAGJZNZ-UHFFFAOYSA-N 0.000 description 3
- 229960000647 gepirone Drugs 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000004381 surface treatment Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 229920003096 Methocel™ K100M Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229920013820 alkyl cellulose Polymers 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000007580 dry-mixing Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- -1 propylmethyl Chemical group 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 239000012748 slip agent Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- JFALSRSLKYAFGM-UHFFFAOYSA-N uranium(0) Chemical compound [U] JFALSRSLKYAFGM-UHFFFAOYSA-N 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
200306866 (1) 玖、發明說明 【發明所屬之技術領域】 本發明係關於一種改善錠劑之表面性質的方法,此錠 劑之基質的纖維素醚含量至少5 5 %。 【先前技術】 修飾藥用錠劑之表面性質有數種不同的目的。此通常 藉由塗覆錠劑而達成。此目的可用以影響活性成份的釋出 模式,用以影響在胃腸系統中的位置(調合物在分解或活 性成份釋出的位置)。此外,塗層可藉改善表面性質以改 善外觀,使得容易操作或者在操作期間內減少塵粒,或掩 飾某些成份的味道。塗覆技巧歷史久遠且須長時間竭力完 成(Gennaro 等人,Remington,The Science and Practice of Pharmacy, 2 0th ed,Publisher Lippincott Williams & Wilkins, Baltimore, USA, Chapter 46 Coating of pharmaceutical dosage forms)。因此,更令人罰1異的是全 新且極簡單的錠劑表面處理原理仍能加諸於此技術。就用 以減少錠劑處理期間內之塵粒形成的調合物及錠劑和經包 裝的錠劑之由使用者運送和操作而言,現發現到,其基質 包含至少5 5 %纖維素醚的錠劑之表面性質可藉由使錠劑短 暫暴於含水溶劑而獲得改善。 製造和包裝錠劑及運送在包裝中的錠劑時,基質包含 至少5 5%纖維素醚的那些錠劑會因粉碎(錠劑與其他材料 接觸之耗損)或因磨擦(因錠劑之間的接觸造成錠劑的耗損) -6 - (2) (2)200306866 而成爲鬆散的顆粒。以乾式混合法,未使用造粒液體地製 得具定義特性的錠劑。藉此,通常藉由以塗覆材料處理錠 劑表面並藉此在錠劑上添加另外一層組成而解決。新發明 的方法中,改變表面性質但此並非藉由添加其他材料而達 成。錠劑表面暴於溶劑,亦於處理期間內移除此溶劑。以 溶劑噴灑於錠劑上可得到較佳效果。利用噴灑技巧,使溶 劑在與錠劑表面接觸之後迅速蒸發。溶劑與表面的此短暫 接觸期間內,表面改變成小顆粒耗損較小的表面。此外, 未經處理的錠劑之較粗糙表面使得彩色錠劑有較非光澤外 觀,在以含水溶劑噴灑和乾燥之後,此程度降低。 【發明內容】 瞭解改善錠劑之表面性質的方法是在錠劑上形成表層 以改變其表面性質的方法。根據本發明而形成之改變的表 面不一定是因形成不同化學組成的層所造成,其可源自使 錠劑短暫暴於含水溶劑而改表錠劑外層物性而得。此可暫 時形成凝膠層,其於溶劑蒸發之後,會形成具所欲性質的 薄層。可以推測此新形成的層構造引發本發明之效應。 若未以根據本發明之方法處理,其基質含至少55%纖 維素醚的錠劑基本上是具有會形成塵粒表面的麻煩錠劑。 其高含量和載體性質使得錠劑具有這樣的表面。纖維素醚 作爲乾式混合錠劑的載體,作爲濕式造粒的黏合劑並可用 於塗覆技巧作爲成膜聚合物。 纖維素醚是載體,其與水形成凝膠。這樣的載體在外 (3) (3)200306866 層吸水之後會較長時間留住其他成份,因此適用於長效調 合物。這樣的載體例可爲羥基-(1C-3C)烷基(1C-3C)烷基 纖維素,如:羥基甲基纖維素、羥基乙基纖維素和較佳的 羥基丙基纖維素。其他形成凝膠的載體可見於藥用可接受 載體和賦形劑的標準編輯品,Handbook of Pharmaceutical Excipient (第 3 版,Arthur H Kibbe 編輯;American Pharmaceutical Association, Washington D C 和 The Pharmaceutical Press, London 於 2000 年印 fj ) 0 此纖維素醚和其性質的相關理論回顧討論於 Alderman,A,A review of cellulose ethers in hydrophilic matrices for oral controlled-release dosage forms, Int J P harm Tech & Prod Mfr,V ο 1 5, Pages 1-9,1 984 o 【實施方式】 使錠劑暴於含水溶劑可以簡單地藉醫藥科學技術(請 參考如:前述教科書 Remington, the Science and Practice of Pharmacy中所述技巧例)中習用的技術以各式各樣方式 完成。較佳方法是噴霧。此方法期間內,錠劑基本上短時 間暴於溶劑。溶劑以液滴形式噴於錠上,衝擊錠劑表面之 後,其迅速蒸發。設定噴霧條件,使得在表面完全潤濕和 發黏之前’自錠表面移除溶劑。過多溶液長時間留在錠劑 表面上時’這些會使得表面過度變形或受損。調整至最合 宜的設備組件和處理參數以得到令人滿意的結果。此完全 在嫻於此技術者使處理最適合的經驗內,此處理的目的是 -8 - (4) (4)200306866 要短時間潤濕淀劑表面以將表面修飾至減少塵粒形成的狀 態。Porter,Bruno and Kackson 於 Lieberman,H A and Lachman L,編輯的手冊 Parmaceutical dosage forms, Tablets,Vo lumn 3提出一個有益的論題用以解釋類似潤濕 塗覆技巧中包含的問題。達到本發明之效果,藉此技數可 利用之方法,藉處理錠劑而減少塵粒形成。肉眼觀察塵粒 形成及觸摸錠劑並能察覺此效果,但可以標準化的易碎性 /磨鈾試驗進行更精準的測定。 含水溶劑是水或對等的極性、氫鍵結溶劑或這樣的溶 劑之混合物。水及水和乙醇之混合物是最常用的這些溶劑 例。當然,藥用上,也可以僅使用這樣的溶劑(請參考前 文提及的Kibbo,2000)。 基質由纖維素醚構成的錠劑之形成塵粒的問題的嚴重 程度視其他構份的本質和量而定,根據本發明之方法以施 用於基質含至少65%纖維素醚的錠劑爲佳,施用於基質含 70至85重量%纖維素醚的錠劑更佳。特別地,就未經處 理的錠劑而言,碳水化合物黏合劑的量由7至1 〇重量% 可能造成問題。碳水化合物黏合劑如:纖維素(微晶狀纖 維素,如:Avicel pH 101)、糖、澱粉、澱粉纖維、糊精 、麥芽糊精、樹膠和藻酸鹽。 用於根據本發明之方法的錠劑總重不超過4 5 0毫克’ 活性成份gepirone HC1 (高至錠劑的13至21重量%)的相 對量高,其量超過纖維素聚合物基質材料並亦超過碳水化 合物黏合劑。利用本發明,仍能於較後的操作期間內製得 -9- (5) (5)200306866 安定性足夠的高含量錠劑。 根據本發明之方法得到的錠劑爲此技術中新穎者,_ 爲本發明之實施例。 實例 錠劑 以下列組成製得錠劑 成份 毫克 功用 Gepirone HC1 80 0 主要活性物 羥基丙基甲基纖維素( Methocel K100M, Premium) 290 0 控制藥物釋出的聚合物 微晶纖維素(Avicel pH 101 33 7 稀釋劑/黏合劑 Euroxide yellow 和 Euroxide red (E7055 和 E70 1 6) 3 5 著色劑 膠態二氧化矽(cab-o-sil M5) 16 助滑劑 硬脂酸鎂NF 12 潤滑劑 製法 活性預混合物: 膠態二氧化砂、著色劑(Euroxide yellow E7055和 -10- (6) (6)200306866
Euroxide red E7016)、Gepirone HC1 粉末和 20% 經基丙基 甲基纖維素移至2立方呎行星式混合機(Hobart Mixer)中 。成份於行星式混合機(Hobart Mixer)中混合15分鐘。標 示爲”活性預混合物π。 用於塡充的摻合物 使用有孔的板No 0020,活性預混合物於Fitzmill中 高速硏磨,向前擠壓以使存在的團塊(若有的話)破碎。 將活性預混合物移至1 0立方呎無I-條狀物的V型摻 合器,通過#12網目篩網並將剩餘的80%HPMC、微晶纖 維素和5〇%硬脂酸鎂移至無I-條狀物的V型摻合器中。 於V型摻合機中摻合成份24分鐘並標示爲”用於塡充的摻 合物’’。 塡充 使用7/8吋平面斜角簡單工具,使用旋轉式Kikusui-Hercules壓縮機械,將摻合物壓入塡充模具中。 此方法中,控制: 重量: 2250毫克 硬度= 7kp 目標厚度: 0 2 5 5 吋 最終慘合 -11 - (7) (7)200306866 使用有孔的板No 0090,塡充物於S S Fitzmill中以 螺旋進料器以中等速率硏磨,向前擠壓。將經硏磨的物質 移至1 0立方呎無I -條狀物的V型摻合器中。剩餘的5 0 % 硬脂酸鎂過篩通過#18網目並移至V-摻合器中。摻合6分 鐘。 使用0 3 3 8吋x0 4 05吋Ovoid矩形模具,以旋轉式 Kikusui-Libra壓縮機壓縮錠劑。 方法中,控制: 操作重量,毫克 4 1 0± 29 硬度5 k p 20± 8 目標厚度,吋 0 23 5 至 0 265 儲存於緊密容器中直到進一步塗覆。 表面處理 7公斤錠劑以1 5 00毫升水於Glatt塗覆機中噴霧。 此塗覆設備經預熱(輸入的空氣溫度6〇°C至65°C ), 之後塗覆盤裝滿錠劑。輸出空氣溫度設定爲40 °C,空氣 體積是3 00立方米/小時。錠劑的初溫熱(1分鐘)和第一 個1〇分鐘塗覆期間內,使用較低旋轉速率(6rpm)以降低 錠劑的磨損/粉碎情況。1 〇分鐘之後,旋轉速率提高至 1 2 5rpm,錠劑塗覆之後乾燥1分鐘(總處理時間約70分 鐘;噴霧速率20至25毫升/分鐘)。以肉眼觀察此表面 -12 - (8) (8)200306866 處理程序。每隔1 〇分鐘取得樣品。 塵粒形成的測試法 A) 肉眼觀察 B ) 每個塑膠容器進行1 0個錠劑的機械試驗 鏡劑震動設定:200rpm,水平震幅:45毫米,測試 時間:45分鐘。稱重定出質量損失。稱重之前,以真空 潔淨錠劑。 結果 肉眼觀察 相對於經水處理的錠劑,未經處理的錠劑淸楚顯現形 成塵粒情況。未經水噴灑表面處理製得的錠劑是紅/粉紅 色。經水處理的錠劑顏色較深並維持安定,即使經70分 鐘處理和之後於烘箱中於5 0 °C乾燥2小時亦然。切割經 水處理的錠劑,可以淸楚看見較深色外層。 塵粒形成測定 下面的附表列出試驗期間內形成的塵粒平均量。 -13- (9) (9)200306866 處理 形成的塵粒平均量(n = 3,%) 未經處理的錠劑 3 04 經水處理(1 〇分鐘)和乾燥 0 03 經水處理(70分鐘)和乾燥 0 03 經水處理(7 〇分鐘和額外於 0 04 5 0 °C乾燥2小時) 由此附表可淸楚看出,僅以水噴灑(即使僅噴灑1 0分 鐘,之後,共200毫升水噴灑於7公斤錠劑上)便能明顯 降低塵粒形成。
Claims (1)
- 200306866 ⑴ 拾、申請專利範園 1 一種用以改善錠劑之表面性質的方法,此錠劑之 基質的纖維素醚含量至少5 5%,其特徵在於此方法包含使 錠劑短暫地暴於含水溶劑。 2 如申請專利範圍第1項之方法,其中基質的纖維 素醚含量至少6 5 %。 3 如申請專利範圍第2項之方法,其中基質的纖維 素醚含量由70至85重量%。 4 如申請專利範圍第1 -3項中任何一項之方法,其 中錠劑另包含7至1 〇重量%碳水化合物黏合劑。 5 —種錠劑,其得自如申請專利範圍第1 -4項中任 何一項之方法。 200306866 陸、(一) (二) 、本案指定代表圖為:第盖_圖 、本代表圖之元件代表符號簡單說明:無 柒、本案若有化學式時,請揭示最能顯示發明特徵的化學 式:無
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02076837 | 2002-05-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200306866A true TW200306866A (en) | 2003-12-01 |
Family
ID=29414765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW092108690A TW200306866A (en) | 2002-05-07 | 2003-04-15 | A method to improve surface properties of pharmaceutical tablets |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20060093665A1 (zh) |
| EP (1) | EP1505956B1 (zh) |
| JP (1) | JP2005529912A (zh) |
| CN (1) | CN100493613C (zh) |
| AR (1) | AR039875A1 (zh) |
| AT (1) | ATE353634T1 (zh) |
| AU (1) | AU2003240776B2 (zh) |
| BR (1) | BR0309735A (zh) |
| CA (1) | CA2484641A1 (zh) |
| CY (1) | CY1106460T1 (zh) |
| DE (1) | DE60311796T2 (zh) |
| DK (1) | DK1505956T3 (zh) |
| ES (1) | ES2282633T3 (zh) |
| IL (1) | IL164738A (zh) |
| MX (1) | MXPA04011021A (zh) |
| PE (1) | PE20031050A1 (zh) |
| PL (1) | PL205139B1 (zh) |
| PT (1) | PT1505956E (zh) |
| SI (1) | SI1505956T1 (zh) |
| TW (1) | TW200306866A (zh) |
| WO (1) | WO2003094896A1 (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116493222B (zh) * | 2023-04-28 | 2024-06-21 | 广东利元亨智能装备股份有限公司 | 涂布烘箱装调方法、装调设备、涂布烘箱及涂布机 |
| CN116983275B (zh) * | 2023-08-02 | 2024-06-25 | 湖南明瑞制药股份有限公司 | 一种奥利司他胶囊制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4302440B1 (en) * | 1980-07-31 | 1986-08-05 | Easily-swallowed, powder-free and gastric-disintegrable aspirin tablet thinly-coated with hydroxypropyl methylcellulose and aqueous spray-coating preparation thereof | |
| GB8616669D0 (en) * | 1986-07-09 | 1986-08-13 | Merk Sharpe & Dohme Ltd | Pharmaceutical compositions |
| US5221543A (en) * | 1986-10-22 | 1993-06-22 | Firma Wilhelm Fette Gmbh | Method of making a fast release stabilized aspartame ingredient for chewing gum |
| US5478572A (en) * | 1994-09-06 | 1995-12-26 | Bristol-Myers Squibb Co. | Gepirone dosage form |
| JP2000119181A (ja) * | 1998-10-06 | 2000-04-25 | Kureha Chem Ind Co Ltd | エスクレチン及びその誘導体の放出制御経口製剤 |
-
2003
- 2003-04-15 TW TW092108690A patent/TW200306866A/zh unknown
- 2003-04-29 ES ES03730190T patent/ES2282633T3/es not_active Expired - Lifetime
- 2003-04-29 MX MXPA04011021A patent/MXPA04011021A/es active IP Right Grant
- 2003-04-29 DE DE60311796T patent/DE60311796T2/de not_active Expired - Fee Related
- 2003-04-29 BR BR0309735-8A patent/BR0309735A/pt not_active IP Right Cessation
- 2003-04-29 AU AU2003240776A patent/AU2003240776B2/en not_active Ceased
- 2003-04-29 DK DK03730190T patent/DK1505956T3/da active
- 2003-04-29 WO PCT/EP2003/050134 patent/WO2003094896A1/en not_active Ceased
- 2003-04-29 AT AT03730190T patent/ATE353634T1/de not_active IP Right Cessation
- 2003-04-29 US US10/513,317 patent/US20060093665A1/en not_active Abandoned
- 2003-04-29 CA CA002484641A patent/CA2484641A1/en not_active Abandoned
- 2003-04-29 EP EP03730190A patent/EP1505956B1/en not_active Expired - Lifetime
- 2003-04-29 JP JP2004502982A patent/JP2005529912A/ja active Pending
- 2003-04-29 CN CNB03810203XA patent/CN100493613C/zh not_active Expired - Fee Related
- 2003-04-29 SI SI200330728T patent/SI1505956T1/sl unknown
- 2003-04-29 PT PT03730190T patent/PT1505956E/pt unknown
- 2003-04-29 PL PL372694A patent/PL205139B1/pl not_active IP Right Cessation
- 2003-05-05 PE PE2003000436A patent/PE20031050A1/es not_active Application Discontinuation
- 2003-05-06 AR ARP030101581A patent/AR039875A1/es unknown
-
2004
- 2004-10-20 IL IL164738A patent/IL164738A/en not_active IP Right Cessation
-
2007
- 2007-04-11 CY CY20071100501T patent/CY1106460T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003240776A1 (en) | 2003-11-11 |
| IL164738A0 (en) | 2005-12-18 |
| WO2003094896A1 (en) | 2003-11-20 |
| AU2003240776B2 (en) | 2008-04-03 |
| BR0309735A (pt) | 2005-02-09 |
| CN100493613C (zh) | 2009-06-03 |
| PL205139B1 (pl) | 2010-03-31 |
| CY1106460T1 (el) | 2011-10-12 |
| ES2282633T3 (es) | 2007-10-16 |
| CA2484641A1 (en) | 2003-11-20 |
| SI1505956T1 (sl) | 2007-08-31 |
| MXPA04011021A (es) | 2005-02-14 |
| DK1505956T3 (da) | 2007-06-11 |
| PL372694A1 (en) | 2005-07-25 |
| ATE353634T1 (de) | 2007-03-15 |
| US20060093665A1 (en) | 2006-05-04 |
| DE60311796D1 (de) | 2007-03-29 |
| IL164738A (en) | 2008-08-07 |
| JP2005529912A (ja) | 2005-10-06 |
| EP1505956A1 (en) | 2005-02-16 |
| PT1505956E (pt) | 2007-04-30 |
| EP1505956B1 (en) | 2007-02-14 |
| DE60311796T2 (de) | 2007-11-22 |
| CN1652751A (zh) | 2005-08-10 |
| PE20031050A1 (es) | 2003-12-23 |
| AR039875A1 (es) | 2005-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010053143A (ja) | 口腔内速崩壊性医薬組成物およびその製造方法 | |
| CN107737112B (zh) | 一种来曲唑片及其制备方法 | |
| JPH04159217A (ja) | 徐放性製剤およびその製造方法 | |
| JP4280074B2 (ja) | マルチプルユニット型徐放性錠剤 | |
| UA75831C2 (en) | Process for preparation of tablets from pharmaceutically active ingredients having unfavourable tabletting properties with the use of granulating liquid containing microcrystalline cellulose | |
| KR101796628B1 (ko) | 콜린알포세레이트를 함유하는 방습성 정제, 및 이의 제조방법 | |
| TW200306866A (en) | A method to improve surface properties of pharmaceutical tablets | |
| JP4812211B2 (ja) | 低用量錠剤および調製方法 | |
| JP4293572B2 (ja) | ロキソプロフェン・ナトリウム含有錠剤 | |
| Chen et al. | Combined application of extrusion-spheronization and hot-melt coating technologies for improving moisture-proofing of herbal extracts | |
| KR101497508B1 (ko) | 펠라고니움 시도이데스 추출물 및 규산 화합물을 포함하는 고형 제제 및 이의 제조 방법 | |
| CN114364375A (zh) | 快速固化化合物 | |
| JP7720226B2 (ja) | リバーロキサバン含有口腔内崩壊錠 | |
| KR100857061B1 (ko) | 바키늄 미르틸루스 추출물을 함유하는 정제 및 이의 제조방법 | |
| CN104146977A (zh) | 一种泮托拉唑钠肠溶片及其制备方法 | |
| CA2944900C (en) | Disintegrating monolithic modified release tablets containing quadri-layer extended release granules | |
| KR101578627B1 (ko) | 실로도신의 용출 특성이 향상된 약제학적 제제 | |
| CN110251476B (zh) | 一种恩曲他滨替诺福韦药物组合物 | |
| HUP0302459A2 (hu) | Eljárás tabletták előállítására növényi extraktumokból | |
| JP3815301B2 (ja) | 成型製剤及びその製法 | |
| RU2257890C2 (ru) | Способ получения устойчивых фармацевтических композиций в форме таблеток, содержащих омепразол, и фармацевтические композиции, полученные таким способом | |
| RU2224507C1 (ru) | Способ получения сахарной крупки | |
| CN112601606A (zh) | 新颖、精益且环境友好的制粒方法 | |
| JP2000072660A (ja) | 凍結解凍造粒法 | |
| SK284766B6 (sk) | Spôsob prípravy pevnej kompozície na báze metoprololu |